Amgen Inc AMGN

Healthcare Biotechnology

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

NDAQ:AMGN - Post by User

Amgen Inc

Bullboard Posts

Comment by mhoganon Jan 17, 2000 2:49pm

138 Views

Post# 1239802

RE: Positive sentiment

On Wednesday, Amgen announced that it intends to spend $850-$900 million on research and development this year. Also last week, fellow Biotech heavyweight, Biogen, pre-released good results which should bode well for Amgen's release. Over the past two weeks, there have been several recent upgrades and price target revisions for Amgen. Paine Webber raised its price target from $60 to $80. Dennis Harp, the analyst at Deutsche Banc Alex Brown termed the company "a bargain" relative to the earnings multiples of its peers in the industry.

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions